| Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation. | Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation.
Brandhofer M, Hoffmann A, Blanchet X, Siminkovitch E, Rohlfing AK, El Bounkari O, Nestele JA, Bild A, Kontos C, Hille K, Rohde V, Fröhlich A, Golemi J, Gokce O, Krammer C, Scheiermann P, Tsilimparis N, Sachs N, Kempf WE, Maegdefessel L, Otabil MK, Megens RTA, Ippel H, Koenen RR, Luo J, Engelmann B, Mayo KH, Gawaz M, Kapurniotu A, Weber C, von Hundelshausen P, Bernhagen J., Free PMC Article | 10/1/2022 |
| Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells. | Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells.
Kaczor DM, Kramann R, Hackeng TM, Schurgers LJ, Koenen RR., Free PMC Article | 03/5/2022 |
| CXCL4L1 promoter variants may protect against the development of renal inflammation in diabetes by increasing CXCL4L1 expression, which in turn activates the anti-inflammatory SMAD7 and IkappaBalpha factors in mesangial cells. | CXCL4L1 Promoter Polymorphisms Are Associated with Improved Renal Function in Type 1 Diabetes.
Armbrust T, Millis MP, Alvarez ML, Saremi A, DiStefano JK, Nourbakhsh M. | 10/26/2019 |
| CXCL4 and CXCL4L1 shift the angiogenic/angiostatic balance in favor of angiostasis. CXCL4L1 in particular was found to be a more potent angiostatic, anti-tumoral and anti-metastatic chemokine, which was verified in different in vivo models. | CXCL4 and CXCL4L1 in cancer.
Ruytinx P, Proost P, Struyf S. | 10/26/2019 |
| Fibstatin and CXCL4L1 cooperate to inhibit endothelial cell proliferation, migration and tubulogenesis in vitro. | CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.
Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B, Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B. | 10/26/2015 |
| CXCL4 and CXCL4L1 activated p38 MAPK, as well as Src kinase within 30 and 5 min, respectively. Extracellular signal-regulated kinase (ERK) phosphorylation occurred in activated lymphocytes. | CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
Van Raemdonck K, Gouwy M, Lepers SA, Van Damme J, Struyf S. | 02/7/2015 |
| fibstatin and CXCL4L1 have cooperative roles in inhibition of tumor invasion in lymph nodes | CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.
Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B, Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B. | 03/29/2014 |
| Structural insight into the novel functional properties of human CXCL4L1. | Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1.
Kuo JH, Chen YP, Liu JS, Dubrac A, Quemener C, Prats H, Bikfalvi A, Wu WG, Sue SC., Free PMC Article | 07/13/2013 |
| PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function | PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function.
De Sutter J, Van de Veire NR, Struyf S, Philippé J, De Buyzere M, Van Damme J., Free PMC Article | 09/1/2012 |
| Current knowledge on the role of CXCL4/PF-4 and CXCL4L1/PF-4var in physiological and pathological processes. | The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
Vandercappellen J, Van Damme J, Struyf S. | 06/25/2011 |
| CXCL4L1 may act angiostatically causing random endothelial cell locomotion, disturbing directed migration towards angiogenic chemokines, serving as a homeostatic chemokine with moderate structural distinction yet different functional profile from CXCL4. | CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment.
Sarabi A, Kramp BK, Drechsler M, Hackeng TM, Soehnlein O, Weber C, Koenen RR, Von Hundelshausen P. | 05/7/2011 |
| both CXCR3A and CXCR3B are implicated in the chemotactic and vascular effects of CXCL4L1. | Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J., Free PMC Article | 02/26/2011 |
| The study determines the binding parameters of CXCL4 and CXCL4L1 for heparin, heparan sulfate, and chondroitin sulfate B. | Functional divergence between 2 chemokines is conferred by single amino acid change.
Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG, Bikfalvi A, Prats H. | 01/15/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (2) articlesNew genetic associations detected in a host response study to hepatitis B vaccine.
Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. Modulation of cystic fibrosis lung disease by variants in interleukin-8.
Hillian AD, Londono D, Dunn JM, Goddard KA, Pace RG, Knowles MR, Drumm ML, CF Gene Modifier Study Group. | 07/2/2008 |